# Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

> **NCT05625477** · PHASE2 · COMPLETED · sponsor: **Zhuhai Trinomab Pharmaceutical Co., Ltd.** · enrollment: 240 (actual)

## Conditions studied

- Tetanus

## Interventions

- **BIOLOGICAL:** TNM002 (low dose)
- **BIOLOGICAL:** TNM002 (medium dose)
- **BIOLOGICAL:** TNM002 (high dose)
- **BIOLOGICAL:** HTIG
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05625477
- **Lead sponsor:** Zhuhai Trinomab Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-18
- **Primary completion:** 2022-05-29
- **Final completion:** 2022-10-18
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05625477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05625477, "Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05625477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*